无抽搐电休克与传统电休克治疗精神分裂症对照研究

目的探讨传统电休克和元抽搐电休克治疗精神分裂症患者在疗效方面的差异以及对患者血清肌酸磷酸激酶（CPK）的影响。方法对110例符合入组标准的精神分裂症患者随机分为无抽搐电休克（MECT）治疗组和传统电体克（ECT）治疗组，每周治疗3次，9次为1疗程，采用阳性与阴性症状量表（PANSS）及副反应量表（TESS）评定疗效及不良反应，于首次治疗前和治疗后第1、4、16周各评定1次，在首次治疗前的晨6时及第1、4、16周治疗后立即采集空腹肘静脉血3ml，用酶法测定，血清CPK。结果治疗前后比较，两组均在第1周末开始PANSS总分及各因子分与治疗前相比差异即有统计学意义（t=2．63～6．41，P均（0．01），且这种差异一直持续到第16周末。治疗结束后，组间比较，两组各时点PANSS和TESS评分差异均无统计学意义（P〉0．05）。两组治疗前后血清CPK测定结果显示，组内及组间比较差异均无显著性（P〉0．05）。结论MECT治疗精神分裂症患者与ECT相比，具有同样的疗效，不良反应未见增加。

Control Study on MECT and ECT in Treatment of schizophrenia

Objective To compare the effects and CPK differences of the MECT and ECT in treatment of schizophrenia. Methods A total of 110 inpatients with schizophrenia were randomly assigned to receive MECT or ECT for 9 times therapy. The Positive and Negative Syndrome Scale（PANSS）, Treatment Emergent symptoms scale （TESS） and CPK were used to measure therapeutic efficacy and side effects . Results Pre-treatmennt,PANSS,TESS scores and CPK did not differ between the two groups . The PANSS scores decreased significantly in both groups after 1,4,16week treatment （P〈0.01）. TESS scores and CPK did not differ between the two groups. After treatmennt,PANSS and TESS scores did not differ between the two groups. Conclusion The results indicated that MECT had the same effects with ECT in treating schizophrenia and did not increase the side effects.